Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-26T09:31:48.388Z Has data issue: false hasContentIssue false
  • English
  • Français

Determination of minor quantities of linezolid polymorphs in a drug substance and tablet formulation by powder X-ray diffraction technique

Published online by Cambridge University Press:  02 March 2017

Mengying Sun ,
Xiurong Hu ,
Xinbo Zhou  and
Jianming Gu
Mengying Sun
Affiliation:
Department of Chemistry, Zhejiang University, Hangzhou, China College of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou, China
Xiurong Hu*
Affiliation:
Department of Chemistry, Zhejiang University, Hangzhou, China
Xinbo Zhou
Affiliation:
College of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou, China
Jianming Gu
Affiliation:
Department of Chemistry, Zhejiang University, Hangzhou, China
*
a)Author to whom correspondence should be addressed. Electronic mail: huxiurong@zju.edu.cn
Get access Rights & Permissions [Opens in a new window]

Abstract

Linezolid (LZD) is one of the first commercially available synthetic oxazolidinone antibiotics and is widely used for the treatment of multidrug-resistant Gram-positive bacterial infection. LZD was found to have five polymorphic forms. The most stable and commercialized polymorphs are known as forms II and IV. Trace content of form II in LZD form IV will cause to transition LZD form IV to II rapidly. Powder X-ray diffraction (PXRD) methods were evaluated for the determination of the polymorphic content of the drug substance and drug product. The estimated limit of detection values of the single peak method for LZD polymorph form II in drug substance and tablet formulation were 0.4 and 0.6%, respectively, while the limit of detection value of Rietveld Refinement (full-profile fitting) evaluated LZD polymorph form II in drug substance was 0.2%. The results clearly show that levels <1 wt.% (in active pharmaceutical ingredients) and 2 wt.% (in tablets) LZD form II in form IV can be detected and quantified by PXRD. Validation of the analytical method proved that the method is repeatable, sensitive, and accurate.

Keywords

Linezolidpolymorphic formpowder X-ray diffractionquantitative analysis
Type
Technical Articles
Information
Powder Diffraction , Volume 32 , Issue 2 , June 2017 , pp. 78 - 85
Check for updates
Copyright
Copyright © International Centre for Diffraction Data 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Aronhime, J., Koltai, T., Braude, V., Fine, S., and Niddam, T. (2006). WO 2006/110155.Google Scholar
Aronhime, J., Koltai, T., Braude, V., Fine, S., and Niddam, T. (2008). US patent 0319191A1.Google Scholar
Bergren, M. S. (2003). US patent 6,559,305 B1.CrossRefGoogle Scholar
Birminghan, M. C., Rayner, C. R., Meagher, A. K., Flavin, S. M., Batts, D. H., and Schentang, J. J. (2003). “Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program,” Clin. Infect. Dis. 36(2), 159–168.CrossRefGoogle Scholar
Byrn, S. R., Pfeiffer, R. R., and Stowell, J. G. (1999). Solid-State Chemistry of Drugs (SSCI, Inc., West Lafayette, Indiana), 2nd ed. Google Scholar
Censi, R. and Martino, P. (2015). “Polymorph impact on the bioavailability and stability of poorly soluble drugs,” Molecules 20, 18759–18776.CrossRefGoogle ScholarPubMed
Chieng, N., Rades, T., and Aaltonen, J. (2011). “An overview of recent studies on the analysis of pharmaceutical polymorphs,” J. Pharm. Biomed. Anal. 55(4), 618–644.Google Scholar
Hestnes, K. H. and Sørensen, B. E. (2012). “Evaluation of quantitative X-ray diffraction for possible use in the quality control of granitic pegmatite in mineral production,” Miner. Eng. 39, 239–247.Google Scholar
Ibánez, J., Font, O., Moreno, N., Elvira, J. J., Alvarez, S., and Querol, X. (2013). “Quantitative Rietveld analysis of the crystalline and amorphous phases in coal,” Fuel 105, 314–317.CrossRefGoogle Scholar
International Conference on Harmonization (ICH) (1999). Harmonized Tripartite Guideline, Specification: Test procedures and acceptance criteria for new drug substances and new drug products: Chemical substances.Google Scholar
International Conference on Harmonization (ICH) (2003). Technical Requirements for the Registration of Pharmaceuticals for Human Use, Stability Testing of New Drugs Substance and Products Q1A (R2).Google Scholar
International Conference on Harmonization (ICH) (2005). Technical Requirements for the Registration of Pharmaceuticals for Human Use, Validation of analytical procedures: Text and methodology Q2(R1).Google Scholar
Kavuru, P., Grebinoski, S. J., Patel, M. A., Wojtas, L., and Chadwick, K. (2016). “Polymorphism of vanillin revisited: the discovery and selective crystallization of a rare crystal structure,” CrystEngComm 18, 1118–1122.Google Scholar
Kim, H. J. and Kim, K. J. (2009). “Quantitative study on polymorphic form in solution crystallization of clopidogrel hydrogen sulfate,” J. Ind. Eng. Chem. Res. 48(24), 11133–11139.Google Scholar
Lee, A. Y. (2011). “Crystal polymorphism in chemical process development,” Annu. Rev. Biomol. Eng. 2, 259–280.Google Scholar
Maccaroni, E., Alberti, E., Malpezzi, L., Masciocchi, N., and Vladiskovic, C. (2008). “Polymorphism of linezolid: a combined single-crystal, powder diffraction and NMR study,” Int. J. Pharm. 351(1–2), 144–151.Google Scholar
Német, Z., Sajó, I., and Demete, Á. (2010). “Rietveld refinement in the routine quantitative analysis of famotidine polymorphs,” J. Pharm. Biomed. Anal. 51(3), 572–576.CrossRefGoogle ScholarPubMed
Qiu, J. B., Li, G., Sheng, Y., and Zhu, M. R. (2015). “Quantification of febuxostat polymorphs using powder X-ray diffraction technique,” J. Pharm. Biomed. Anal. 107(25), 298–303.Google Scholar
Rao, D. M. and Reddy, P. K. (2010). US patent 7,714,128 B2.Google Scholar
Raw, A. S., Furness, M. S., Gill, D. S., Adams, R. C., Holcombe, F. O. Jr., and Yu, L. X. (2004). “Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs),” Adv. Drug Deliv. Rev. 56(3), 397–414.CrossRefGoogle ScholarPubMed
Ried, J. W. and Hendry, J. A. (2006). “Rapid, accurate phase quantification of multiphase calcium phosphate materials using Rietveld refinement,” J. Appl. Crystallogr. 39(4), 536–543.Google Scholar
Roberts, S. N. C., Williams, A. C., Grimsey, I. M., and Booth, S. W. (2002). “Quantitative analysis of mannitol polymorphs. X-ray powder diffractometry—exploring preferred orientation effects,” J. Pharm. Biomed. Anal. 28(6), 1149–1159.Google Scholar
Sheikhzadeh, M., Rohani, S., Jutan, A., and Manifar, T. (2007). “Quantitative and molecular analysis of buspirone hydrochloride polymorphs,” J. Pharm. Sci. 96(3), 569–583.Google Scholar
Soares, F. L. and Carneiro, R. L. (2014). “Evaluation of analytical tools and multivariate methods for quantification of co-former crystals in ibuprofen–nicotinamide cocrystals,” J. Pharm. Biomed. Anal. 89(15), 166–175.CrossRefGoogle ScholarPubMed
Tammaro, L., Saturnino, C., D'Aniello, S., Vigliotta, G., and Vittoria, V. (2015). “Polymorphic solidification of linezolid confined in electrospun PCL fibers for controlled release in topical applications,” Int. J. Pharm. 490(1–2), 32–38.CrossRefGoogle ScholarPubMed
Tanaka, R. and Hirayama, N. (2008). “Crystal structure of linezolid,” Anal. Sci. 24, x43–44.Google Scholar
Tiwari, M., Chawla, G., and Bansal, A. K. (2007). “Quantification of olanzapine polymorphs using powder X-ray diffraction technique,” J. Pharm. Biomed. Anal. 43(3), 865–872.Google Scholar
U.S. Food and Drug Administration (2000). “Q6A specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances,” Fed. Regist. 65, 83041–83063.Google Scholar
Virtanen, T. and Maunu, S. L. (2010). “Quantitation of a polymorphic mixture of an active pharmaceutical ingredient with solid state 13C CPMAS NMR spectroscopy,” Int. J. Pharm. 394(1–2), 18–25.Google Scholar
Yarasteh, M., Deng, Z. Y., Hwang, H., Kim, Y. J., and Wong, G.. B. (2009). “Quantitative determination of polymorphic impurity by X-ray powder diffractometry in an OROS® formulation,” Int. J. Pharm. 366, 74–81.Google Scholar
Supplementary material: File

Sun supplementary material

Sun supplementary material

Download Sun supplementary material(File)
File 49.4 KB